Glaxosmithkline Plc Adr Stock Buy Hold or Sell Recommendation
| GSK Stock | USD 33.96 0.26 0.77% |
Considering the 90-day investment horizon and your above-average risk tolerance, our recommendation regarding GlaxoSmithKline PLC ADR is 'Strong Hold'. The recommendation algorithm takes into account all of GlaxoSmithKline PLC's available fundamental, technical, and predictive indicators you will find on this site.
Check out GlaxoSmithKline PLC Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as GlaxoSmithKline and provide practical buy, sell, or hold advice based on investors' constraints. GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
GlaxoSmithKline |
Execute GlaxoSmithKline PLC Buy or Sell Advice
The GlaxoSmithKline recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on GlaxoSmithKline PLC ADR. Macroaxis does not own or have any residual interests in GlaxoSmithKline PLC ADR or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute GlaxoSmithKline PLC's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
GlaxoSmithKline PLC Trading Alerts and Improvement Suggestions
| GlaxoSmithKline PLC generated a negative expected return over the last 90 days | |
| On 10th of October 2024 GlaxoSmithKline PLC paid $ 0.3857 per share dividend to its current shareholders | |
| Latest headline from washingtonexaminer.com: Big Pharma is pretty great, actually |
GlaxoSmithKline PLC Returns Distribution Density
The distribution of GlaxoSmithKline PLC's historical returns is an attempt to chart the uncertainty of GlaxoSmithKline PLC's future price movements. The chart of the probability distribution of GlaxoSmithKline PLC daily returns describes the distribution of returns around its average expected value. We use GlaxoSmithKline PLC ADR price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of GlaxoSmithKline PLC returns is essential to provide solid investment advice for GlaxoSmithKline PLC.
| Mean Return | -0.29 | Value At Risk | -2.56 | Potential Upside | 1.89 | Standard Deviation | 1.53 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of GlaxoSmithKline PLC historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
GlaxoSmithKline Stock Institutional Investors
| Shares | Eversept Partners, Llc | 2024-09-30 | 4.1 M | Provident Trust Company | 2024-09-30 | 4 M | Grantham, Mayo, Van Otterloo & Co., Llc | 2024-09-30 | 3.7 M | Hsbc Holdings Plc | 2024-06-30 | 3.6 M | Hotchkis & Wiley Capital Management Llc | 2024-09-30 | 3.5 M | Equity Investment Corp | 2024-09-30 | 3.5 M | Lmr Partners Llp | 2024-06-30 | 3.3 M | Camber Capital Management Llc | 2024-09-30 | 3 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 2.6 M | Dodge & Cox | 2024-09-30 | 68.1 M | Fmr Inc | 2024-09-30 | 29 M |
GlaxoSmithKline PLC Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | 300M | 119M | 25M | (269M) | (424M) | (402.8M) | |
| Change In Cash | 744M | 431M | (1.4B) | (394M) | (567M) | (538.7M) | |
| Free Cash Flow | 5.9B | 6.2B | 5.0B | 5.1B | 4.0B | 3.4B | |
| Depreciation | 3.0B | 624M | 2.5B | 2.3B | 2.3B | 1.4B | |
| Other Non Cash Items | 814M | 848M | 756M | (433M) | 468M | 491.4M | |
| Capital Expenditures | 2.2B | 2.2B | 2.9B | 2.3B | 2.3B | 1.5B | |
| Net Income | 5.3B | 6.4B | 5.1B | 4.9B | 4.9B | 4.6B | |
| End Period Cash Flow | 4.8B | 5.3B | 3.8B | 3.4B | 2.9B | 2.1B | |
| Dividends Paid | 4.0B | 4.0B | 4.0B | 3.5B | 2.2B | 3.4B | |
| Investments | (5.4B) | 2.2B | 334M | (8.8B) | (1.6B) | (1.5B) | |
| Net Borrowings | 3.5B | (4.2B) | (2.2B) | (4.8B) | (5.5B) | (5.8B) | |
| Change To Netincome | 670M | 380M | 105M | (8.3B) | (9.6B) | (10.1B) |
GlaxoSmithKline PLC Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to GlaxoSmithKline PLC or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that GlaxoSmithKline PLC's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a GlaxoSmithKline stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.34 | |
β | Beta against Dow Jones | 0.31 | |
σ | Overall volatility | 1.45 | |
Ir | Information ratio | -0.28 |
GlaxoSmithKline PLC Volatility Alert
GlaxoSmithKline PLC ADR exhibits very low volatility with skewness of 0.99 and kurtosis of 3.15. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure GlaxoSmithKline PLC's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact GlaxoSmithKline PLC's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.GlaxoSmithKline PLC Fundamentals Vs Peers
Comparing GlaxoSmithKline PLC's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze GlaxoSmithKline PLC's direct or indirect competition across all of the common fundamentals between GlaxoSmithKline PLC and the related equities. This way, we can detect undervalued stocks with similar characteristics as GlaxoSmithKline PLC or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of GlaxoSmithKline PLC's fundamental indicators could also be used in its relative valuation, which is a method of valuing GlaxoSmithKline PLC by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare GlaxoSmithKline PLC to competition |
| Fundamentals | GlaxoSmithKline PLC | Peer Average |
| Return On Equity | 0.22 | -0.31 |
| Return On Asset | 0.0724 | -0.14 |
| Profit Margin | 0.08 % | (1.27) % |
| Operating Margin | 0.08 % | (5.51) % |
| Current Valuation | 85.07 B | 16.62 B |
| Shares Outstanding | 2.04 B | 571.82 M |
| Shares Owned By Insiders | 0.06 % | 10.09 % |
| Shares Owned By Institutions | 15.38 % | 39.21 % |
| Number Of Shares Shorted | 16.29 M | 4.71 M |
| Price To Earning | 11.80 X | 28.72 X |
| Price To Book | 3.93 X | 9.51 X |
| Price To Sales | 2.21 X | 11.42 X |
| Revenue | 30.33 B | 9.43 B |
| Gross Profit | 19.92 B | 27.38 B |
| EBITDA | 9.08 B | 3.9 B |
| Net Income | 4.93 B | 570.98 M |
| Cash And Equivalents | 3.72 B | 2.7 B |
| Cash Per Share | 0.32 X | 5.01 X |
| Total Debt | 18.02 B | 5.32 B |
| Debt To Equity | 0.98 % | 48.70 % |
| Current Ratio | 1.43 X | 2.16 X |
| Book Value Per Share | 3.43 X | 1.93 K |
| Cash Flow From Operations | 6.77 B | 971.22 M |
| Short Ratio | 3.29 X | 4.00 X |
| Earnings Per Share | 1.53 X | 3.12 X |
| Price To Earnings To Growth | 0.73 X | 4.89 X |
| Target Price | 45.95 | |
| Number Of Employees | 70.21 K | 18.84 K |
| Beta | 0.33 | -0.15 |
| Market Capitalization | 69.29 B | 19.03 B |
| Total Asset | 59.01 B | 29.47 B |
| Retained Earnings | 7.74 B | 9.33 B |
| Working Capital | (2.42 B) | 1.48 B |
GlaxoSmithKline PLC Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as GlaxoSmithKline . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About GlaxoSmithKline PLC Buy or Sell Advice
When is the right time to buy or sell GlaxoSmithKline PLC ADR? Buying financial instruments such as GlaxoSmithKline Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having GlaxoSmithKline PLC in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Farming Thematic Idea Now
Farming
Companies producing farming products and providing services for farmers. The Farming theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Farming Theme or any other thematic opportunities.
| View All Next | Launch |
Check out GlaxoSmithKline PLC Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.28) | Dividend Share 0.61 | Earnings Share 1.53 | Revenue Per Share 15.38 | Quarterly Revenue Growth (0.02) |
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.